Literature DB >> 9035104

Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies.

S W Lee1, B A Sullenger.   

Abstract

The muscular weakness and fatigability associated with myasthenia gravis are engendered by autoantibodies directed against acetylcholine receptors on muscle cells at neuromuscular junctions. The pathogenic consequences of this immune response can potentially be modulated by molecules that bind such autoantibodies and block their interaction with these receptors. We report the isolation of a small nuclease-resistant RNA molecule that binds both a rat monoclonal antibody that recognizes the main immunogenic region on the acetylcholine receptor, and autoantibodies from patients with myasthenia gravis. Moreover, this RNA can act as a decoy and protect acetylcholine receptors on human cells from the effects of these antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9035104     DOI: 10.1038/nbt0197-41

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  18 in total

1.  Developing aptamers into therapeutics.

Authors:  R R White; B A Sullenger; C P Rusconi
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing.

Authors:  Xianbin Yang; Suzanne E Bassett; Xin Li; Bruce A Luxon; Norbert K Herzog; Robert E Shope; Judy Aronson; Tarl W Prow; James F Leary; Romy Kirby; Andrew D Ellington; David G Gorenstein
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

Review 3.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

4.  Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Authors:  Ulrich Wuellner; Julia I Gavrilyuk; Carlos F Barbas
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-09       Impact factor: 15.336

Review 5.  Aptamers in immunotherapy.

Authors:  Claudia M Dollins; Smita Nair; Bruce A Sullenger
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

Review 6.  Aptamers as Therapeutics.

Authors:  Shahid M Nimjee; Rebekah R White; Richard C Becker; Bruce A Sullenger
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-01-06       Impact factor: 13.820

7.  Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers.

Authors:  Xianbin Yang; Xin Li; Tarl W Prow; Lisa M Reece; Suzanne E Bassett; Bruce A Luxon; Norbert K Herzog; Judy Aronson; Robert E Shope; James F Leary; David G Gorenstein
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

8.  Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.

Authors:  Byounghoon Hwang; Jung Sun Cho; Hyeon Ju Yeo; Jung-Hye Kim; Kyung Min Chung; Kyungsook Han; Sung Key Jang; Seong-Wook Lee
Journal:  RNA       Date:  2004-07-09       Impact factor: 4.942

9.  Aptamer antagonists of myelin-derived inhibitors promote axon growth.

Authors:  Yuxuan Wang; Zin Z Khaing; Na Li; Brad Hall; Christine E Schmidt; Andrew D Ellington
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

10.  Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides.

Authors:  Enid W Choi; Lalitha V Nayak; Paula J Bates
Journal:  Nucleic Acids Res       Date:  2009-12-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.